Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE: MRK) Q4 2025 Earnings Call dated Feb. 03, 2026 Corporate Participants: Robert Davis — Chairman of the Board, President, Chief…
38 articles, transcripts, and reports
Merck & Co., Inc. (NYSE: MRK) Q4 2025 Earnings Call dated Feb. 03, 2026 Corporate Participants: Robert Davis — Chairman of the Board, President, Chief…
Merck & Co., Inc. (NYSE: MRK) Q2 2025 Earnings Call dated Jul. 29, 2025 Corporate Participants: Peter Dannenbaum — Senior Vice President of Investor Relations…
Merck & Co., Inc. (NYSE: MRK) Q3 2025 Earnings Call dated Oct. 30, 2025 Corporate Participants: Peter Dannenbaum — Senior Vice President, Investor Relations Robert…
Merck & Co., Inc. (NYSE: MRK) reported its third quarter 2025 earnings results today. Total worldwide sales of $17.3 billion were up 4% from the…
Merck (NYSE: MRK) reported its third quarter 2024 earnings results today. Sales grew 4% year-over-year to $16.7 billion. Excluding FX, sales growth was 7%. GAAP…
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported net profit for the second quarter of 2024, on an adjusted basis, compared to a loss…
Merck (NYSE: MRK) reported sales of $16 billion for the third quarter of 2023, up 7% from the same period a year ago. GAAP net…
Merck (NYSE: MRK) reported second quarter 2023 earnings results today. Total worldwide sales were $15 billion, up 3% from the same period a year ago.…
Merck & Co., Inc. (NYSE: MRK) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Robert M. Davis — Chairman and…
Merck & Co Inc (NYSE:MRK) Q4 2022 Earnings Call dated Feb. 02, 2023. Corporate Participants: Peter Dannenbaum — Vice President, Investor Relations Robert M. Davis — Chairman and Chief…